Novo Nordisk will be selling the new 7.2-mg dose under the brand name Wegovy HD. The FDA's decision fell under a new pilot program intended to grant certain companies improved access and quicker approvals.
The Cardiovascular Business Forty Under 40 Class of 2026 represents an accomplished group of clinicians, researchers, entrepreneurs and administrators who are redefining what cardiovascular leadership looks like under the age of 40.
Experts believe this new research offers important insights as practices adopt artificial intelligence in breast imaging, often with an extra out-of-pocket fee.
Dana Smetherman, MD, CEO of the American College of Radiology, discusses the policy, which urges for more robust promotion of low-dose CT as a public health tool.